Email from Allergan about Actavis 11-19-14

I got this letter below from Allergan on 11-19-14 (today) addressing the merging of Actavis and Allergan.  Allergan wanted to stress that they would continue a high quality of research and development as they had before.  Karla from our office sent me a copy of this email which she got, and she wrote that  “It looks like Allergan will become part of Actavis soon.  This email confirms it and reaffirms their commitment to continuing research and development.”

Here’s the letter from Allergan, the makers of our cherished Botox, Juvederm, and Latisse.  For more information about these products, visit our Modesto Botox and Juvederm page.


The fight over Botox!



November 19, 2014

To our valued customers:

As announced in a press release earlier this week, we are pleased to share that Actavis and Allergan have entered into a definitive agreement under which Actavis will acquire Allergan in a deal valued at approximately $66 billion. Bringing our two companies together represents a powerful strategic combination, creating a dynamic, top 10 global pharmaceutical company.

We anticipate that the acquisition will close in 2Q 2015. Until then, it will be business as usual, with no impact to our operations or the high quality of service that you have come to expect from Allergan. Once the transaction closes, we will notify you of any relevant changes, and it is our goal to minimize any possible impact this could have on you, your patients, and our employees.

Like us, the Actavis culture is centered around innovation and customer service, and investment in R&D will remain one of the top priorities of the integrated company. The combined company will offer a broad portfolio of products in Eye Care, CNS/Neurosciences, Medical Aesthetics/Dermatology/Plastic Surgery, Gastroenterology, Women’s Health and Urology and Anti-infective therapeutic categories, as well as the highest quality generic, branded-generic and Over-the-Counter products. The combined company will provide an exceptional level of R&D support, with approximately $1.7 billion invested annually in brands, generics and biopharmaceuticals aimed at delivering high quality products to address unmet patient needs.

We want to thank you for your support and to assure you that we remain dedicated to exceeding your expectations and delivering products and services that make a difference to you and your patients. We look forward to sharing more details of our combined products and services in the future. In the meantime, if you have any questions, please contact your sales representative or visit our websites at and


Brent Saunders, CEO and President, Actavis

David Pyott, Chairman and CEO, Allergan